# AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

> **NCT03965494** · EARLY_PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 10 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** BGB 324 (before surgery)
- **DRUG:** BGB 324 (after surgery)

## Key facts

- **NCT ID:** NCT03965494
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-02
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer - official close date is 10/31/23
- **Last updated:** 2024-02-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03965494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03965494, "AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03965494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*